The suit won't succeed - there's actually good cost-effectiveness data that shows that even at this price Sovaldi and Harvoni are more cost-defective than PEG/riba or PEG/riba/boceprevir due to the much higher SVR rates, shorter duration, and lack of side effects, particularly in cirrhotic patients who are the most likely to go on and develop liver cancer or require liver transplant without cure. Cost pressure by AbbVie and Merck products will bring prices down over time.
BLT Price at posting:
83.0¢ Sentiment: None Disclosure: Not Held
